Completed PHASE4 INTERVENTIONAL 2-arm NCT00190580

Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT)

Sponsor: KVT-Study Group

Conditions Chronic Kidney Disease Hypertension

Interventions Conventional antihypertensive drugs valsartan

Updated 5 times since 2017 Last updated: Mar 30, 2015 Started: Feb 28, 2003 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00190580, this PHASE4 trial focuses on Chronic Kidney Disease and Hypertension and remains completed. Sponsored by KVT-Study Group, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

KVT-Study Group
Kitasato University
Showa University
St. Marianna University School of Medicine
Tokai University
Yokohama City University

Data source: KVT-Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kawasaki, Japan